Skip to main content
. Author manuscript; available in PMC: 2020 Oct 9.
Published in final edited form as: Neurobiol Dis. 2020 Jan 3;136:104725. doi: 10.1016/j.nbd.2019.104725

Fig. 6.

Fig. 6.

Adaptaquin partially prevents the loss of dopaminergic neurons in the substantia nigra of 6-OHDA-injected mice. Representative images (A) of TH immunohistochemistry (brown) with thionin counterstain (blue) showing dopaminergic neurons in the unlesioned (control) or 6-OHDA lesioned (experimental) side of the posterior and anterior regions of the substantia nigra of mice who received a sham surgery or a 6-OHDA lesion and either a control IP injection (6-OHDA) or a daily 30 mg/kg IP injection of AQ for 7 consecutive days (AQ + 6-OHDA). Higher magnification images (B) showing the dopaminergic neurons in the experimental side of the anterior substantia nigra of sham, 6-OHDA and AQ + 6-OHDA mice. Unbiased stereology counts (C) and proportions between the experimental and the control side (D) of the total number of dopaminergic TH+ neurons in all three groups showing that 6-OHDA induces a drastic reduction of the counts (ANOVA with Sidak’s multiple comparison test ****p < .0001) and the proportion (ANOVA with Tukey’s post-hoc test ****p < .0001) of dopaminergic neurons in the substantia nigra, compared to sham mice. AQ post-treatment for 7 days significantly increases both the counts (ANOVA with Sidak’s multiple comparison test ***p < .0005) and the proportion (ANOVA with Tukey’s post-hoc test ***p < .0005) of nigral dopaminergic neurons.